There are 2789 resources available
LBA31 - High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)
Presenter: Jeroen Van Dorp
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1505MO - Improving cancer care through broader access to quality biomarker testing: An IQN Path, ECPC and EFPIA initiative
Presenter: Nicola Normanno
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
1506MO - Incorporating genetic and non-genetic risk factors in breast cancer risk prediction for healthy women with non-informative genetic test result
Presenter: Anja Tüchler
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
389MO - Risk of bowel obstruction in patients undergoing neoadjuvant chemotherapy for high-risk colon cancer: A nested case-control matched analysis of an international, multi-centre, randomised controlled trial (FOxTROT)
Presenter: James Glasbey
Session: Mini oral session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
390MO - Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec, Canada
Presenter: Mustapha Tehfe
Session: Mini oral session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
Discussion 657MO and 658MO
Presenter: Sumanta Pal
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Discussion 654MO, 655MO and 656MO
Presenter: Samra Turajlic
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Discussion 659MO and LBA31
Presenter: Ignacio Duran
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
391MO - Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials
Presenter: Elisabeth Bergen
Session: Mini oral session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
1151MO - Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial
Presenter: Marie Wislez
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast